Human amine receptor

Abstract

A Human amine receptor polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also provided are methods for detecting compounds which bind to and activate and bind to and inhibit such polypeptide and the use of compounds for treating diseases related to the under-expression and over-expression of the Human amine receptor of the present invention. Also disclosed are methods for detecting mutations in the nucleic acid sequence encoding the polypeptide and for detecting altered levels of the soluble form of the polypeptide.

1 . An isolated polynucleotide comprising a member selected from the group consisting of: 
 (a) a polynucleotide encoding the polypeptide as set forth in  FIG. 1 .    (b) a polynucleotide encoding the polypeptide expressed by the DNA contained in ATCC Deposit No. ______;    (c) a polynucleotide capable of hybridizing to and which is at least 70% identical to the polynucleotide of (a) or (b); and    (d) a polynucleotide fragment of the polynucleotide of (a), (b) or (c).    
     
     
         2 . The polynucleotide of  claim 1  encoding the polypeptide of  FIG. 1 .  
     
     
         3 . The polynucleotide of  claim 1  wherein said polynucleotide encodes a mature polypeptide encoded by the DNA contained in ATCC Deposit No. ______.  
     
     
         4 . A vector containing the polynucleotide of  claim 1 .  
     
     
         5 . A host cell genetically engineered with the vector of  claim 4 .  
     
     
         6 . A process for producing a polypeptide comprising: expressing from the host cell of  claim 5  the polypeptide encoded by said polynucleotide.  
     
     
         7 . A process for producing cells capable of expressing a polypeptide comprising genetically engineering cells with the vector of  claim 4 .  
     
     
         8 . A polypeptide selected from the group consisting of (i) a polypeptide having the deduced amino acid sequence of  FIG. 1  and fragments, analogs and derivatives thereof; and (ii) a polypeptide encoded by the cDNA of ATCC Deposit No. ______ and fragments, analogs and derivatives of said polypeptide.  
     
     
         9 . The polypeptide of  claim 8  wherein the polypeptide has the deduced amino acid sequence of  FIG. 1 .  
     
     
         10 . An antibody against the polypeptide of  claim 8 .  
     
     
         11 . A compound which activates the polypeptide of  claim 8 .  
     
     
         12 . A compound which inhibits activation of the polypeptide of  claim 8 .  
     
     
         13 . A method for the treatment of a patient having need to activate a receptor comprising: administering to the patient a therapeutically effective amount of the compound of  claim 11 .  
     
     
         14 . A method for the treatment of a patient having need to inhibit a receptor comprising: administering to the patient a therapeutically effective amount of the compound of  claim 12 .  
     
     
         15 . The method of  claim 13  wherein said compound is a polypeptide and a therapeutically effective amount of the compound is administered by providing to the patient DNA encoding said agonist and expressing said agonist in vivo.  
     
     
         16 . The method of  claim 14  wherein said compound is a polypeptide and a therapeutically effective amount of the compound is administered by providing to the patient DNA encoding said antagonist and expressing said antagonist in vivo.  
     
     
         17 . A method for identifying a compound which bind to and activate the polypeptide of  claim 8  comprising: 
 contacting a compound with cells expressing on the surface thereof the polypeptide of  claim 8 , said polypeptide being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said polypeptide said contacting being under conditions sufficient to permit binding of compounds to the polypeptide; and    identifying a compound capable of polypeptide binding by detecting the signal produced by said second component.    
     
     
         18 . A method for identifying compounds which bind to and inhibit activation of the polypeptide of  claim 8  comprising: 
 contacting an analytically detectable ligand known to bind to the receptor polypeptide and a compound with host cells expressing on the surface thereof the polypeptide of  claim 8 , said polypeptide being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said polypeptide under conditions to permit binding to the polypeptide; and    determining whether the ligand binds to the polypeptide by detecting the absence of a signal generated from the interaction of the ligand with the polypeptide.    
     
     
         19 . A process for diagnosing in a patient a disease or a susceptibility to a disease related to an under-expression of the polypeptide of  claim 8  comprising: 
 determining a mutation in the nucleic acid sequence encoding said polypeptide, or the amount of the polypeptide in a sample derived from a patient.    
     
     
         20 . A diagnostic process comprising: 
 analyzing for the presence of a soluble form of the polypeptide of  claim 8  in a sample derived from a host.